Association between urinary sodium excretion and all-cause mortality: a cohort study in a Chinese community-based population

Table 2 Association of estimated urinary sodium excretion and spot urinary sodium with all-cause mortality

	N	Event (%)	Unadjusted model		Adjusted model 1^*		Adjusted model 2^**
	N	Event (%)	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
Estimated urinary sodium excretion
Q2 (3.90–4.76 g/d)	1627	7 (0.4)	1.00 (reference)	-	1.00 (reference)	-	1.00 (reference)	-
Q1 (< 3.90 g/d)	1628	14 (0.9)	2.00 (0.81,4.96)	0.134	2.13 (0.86,5.28)	0.103	1.83 (0.72,4.68)	0.205
Q3 (4.77–5.75 g/d)	1627	15 (0.9)	2.15 (0.88,5.27)	0.095	1.75 (0.71,4.31)	0.220	1.69 (0.68,4.21)	0.258
Q4 (> 5.75 g/d)	1628	29 (1.8)	4.17 (1.83,9.51)	< 0.001	3.00 (1.31,6.88)	0.009	2.94 (1.27,6.83)	0.012
Spot urinary sodium
Q2 (78-109mmol/L)	1619	15 (0.9)	1.00 (reference)	-	1.00 (reference)	-	1.00 (reference)
Q1 (< 78mmol/L)	1624	16 (1.0)	1.06 (0.53,2.15)	0.867	1.21 (0.60,2.45)	0.600	1.21 (0.58,2.52)	0.609
Q3(110-144mmol/L)	1611	18 (1.1)	1.21 (0.61,2.40)	0.590	1.27 (0.64,2.52)	0.497	1.29 (0.63,2.63)	0.489
Q4(> 144mmol/L)	1656	16 (1.0)	1.04 (0.52,2.11)	0.904	1.08 (0.53,2.20)	0.828	1.12 (0.53,2.36)	0.761

^*Adjusted model 1: Adjusted for age and sex; ^**Adjusted model 2: Further adjusted for body mass index, hypertension, diabetes mellitus, dyslipidemia, cardiovascular disease, antihypertensive medications, antidiabetic medications, antilipidemic medications, and estimated glomerular filtration rate based on Model 1. CI, confidence interval; HR, hazard ratio

ISSN: 1471-2261